Story Jan. 29 - I-Mab: After announcing a pipeline restructure earlier in the month, I-Mab’s has reduced its workforce by around 27%. Story Jan. 28 - Zentalis Pharmaceuticals: In hopes of ...

For the third quarter of 2024, Zentalis Pharmaceuticals reported a ... The San Diego, California-headquartered company is also working on a pipeline of preclinical drug products for target organ ...

Guggenheim decreased their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th.

SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

Zentalis estimates that about half of PROC patients overexpress Cyclin E1 based on its proprietary immunohistochemistry cutoff. As of the January 13, 2025 data cutoff, the safety and tolerability ...

Zentalis Pharmaceuticals has a 1 year low of $1.61 and a 1 year high of $18.07. The firm’s 50 day moving average price is $2.55 and its two-hundred day moving average price is $3.08. Get ...

SAN DIEGO, March 15, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 ...

Preclinical data of azenosertib demonstrating antitumor effects with microtubule inhibitor based ADCs SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq ...

President Donald Trump turned his attention to the Keystone XL Pipeline on Monday evening, calling for the company building it to "come back to America, and get it built — NOW!" Trump said he ...